Literature DB >> 11589350

Peripheral blood neutrophils are hyperresponsive to IL-8 and Gro-alpha in cryptogenic fibrosing alveolitis.

P C Glynn1, E M Henney, I P Hall.   

Abstract

Cryptogenic fibrosing alveolitis (CFA) is characterized by increased pulmonary recruitment of peripheral blood neutrophils (PBNs) by interleukin (IL)-8 and other chemotactic mediators. This study investigated whether, in CFA, the PBN motility response is primed by IL-8 and growth-related oncogene (Gro)-alpha, as demonstrated in other neutrophilic inflammatory diseases, and whether the motility response of PBNs to IL-8 and Gro-alpha can be abrogated using a selective antagonist for the neutrophil receptor for IL-8 and Gro-alpha, CXCR2. The percentage of PBNs to undergo shape change (%SC), spontaneously and in response to IL-8 and Gro-alpha, was measured in patients with CFA (n=10) and controls (n=10), and the effect of the CXCR2 antagonist SB272844 studied. Plasma levels of IL-8, and Gro-alpha were measured using an enzyme-linked immunosorbent assay (ELISA). The %SC of unstimulated PBNs and the potency of Gro-alpha and IL-8 to produce neutrophil polarization was greater in CFA than in controls; dose which produces 50% of maximal effect (EC50) of IL-8 was 3.6 +/- 0.7 nM for CFA versus 6.3 +/- 1.0 nM for controls; p<0.05. SB272844 inhibited Gro-alpha induced but not IL-8 induced neutrophil shape change (equilibrium constant (KD) 123 +/- 18 nM). Plasma concentrations of Gro-alpha were increased in patients with CFA. PBNs are spontaneously activated and undergo a greater motility response to IL-8 and Gro-alpha in CFA. Interleukin-8 and growth-related oncogene-alpha, circulating in substimulatory amounts in cryptogenic fibrosing alveolitis, may prime the peripheral blood neutrophils motility response, thus increasing their capacity for migration to the lung. Selective CXCR2 antagonists may be useful to block the Gro-alpha-induced priming response whilst preserving neutrophil functions mediated by CXCR1, the alternative neutrophil receptor for interleukin-8.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11589350     DOI: 10.1183/09031936.01.00057901

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

1.  The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions.

Authors:  Stipo Jurcevic; Charles Humfrey; Mohib Uddin; Steve Warrington; Bengt Larsson; Christina Keen
Journal:  Br J Clin Pharmacol       Date:  2015-10-02       Impact factor: 4.335

Review 2.  IL-17: an important pathogenic factor in endometriosis.

Authors:  Jia-Lu Shi; Zi-Meng Zheng; Min Chen; Hui-Hui Shen; Ming-Qing Li; Jun Shao
Journal:  Int J Med Sci       Date:  2022-04-11       Impact factor: 3.642

3.  Anti-inflammatory therapy by intravenous delivery of non-heparan sulfate-binding CXCL12.

Authors:  Graeme O'Boyle; Paul Mellor; John A Kirby; Simi Ali
Journal:  FASEB J       Date:  2009-08-10       Impact factor: 5.191

4.  Influence of human T lymphotrophic virus type I on cryptogenic fibrosing alveolitis - HTLV-I associated fibrosing alveolitis: proposal of a new clinical entity.

Authors:  W Matsuyama; M Kawabata; A Mizoguchi; F Iwami; J Wakimoto; M Osame
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

5.  Mitochondrial damage-associated molecular patterns released by abdominal trauma suppress pulmonary immune responses.

Authors:  Cong Zhao; Kiyoshi Itagaki; Alok Gupta; Stephen Odom; Nicola Sandler; Carl J Hauser
Journal:  J Trauma Acute Care Surg       Date:  2014-05       Impact factor: 3.313

6.  Cow Milk Extracellular Vesicle Effects on an In Vitro Model of Intestinal Inflammation.

Authors:  Samanta Mecocci; Alessio Ottaviani; Elisabetta Razzuoli; Paola Fiorani; Daniele Pietrucci; Chiara Grazia De Ciucis; Silvia Dei Giudici; Giulia Franzoni; Giovanni Chillemi; Katia Cappelli
Journal:  Biomedicines       Date:  2022-02-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.